TRANSFORMING OPIOID CARE

SAFE, EVIDENCE-BASED MEDICATION-ASSISTED TREATMENT (MAT) IN CLINICAL PRACTICE

APRNworld

TRANSFORMING OPIOID CARE:

SAFE, EVIDENCE-BASED MEDICATION-ASSISSTED TREATMENT(MAT) IN CLINICAL PRACTICE

ANCC Accredited NCPD Hours: 1 hrs

Target Audience: RN/APRN

NEEDS ASSESSMENT

The opioid epidemic continues to pose a profound public health challenge both in the United States and worldwide. According to the Centres for Disease Control and Prevention (CDC, 2024), over 112,000 Americans died from a drug overdose in 2023, with approximately 75% of these deaths involving opioids. Despite the availability of effective treatments, including pharmacologic options such as buprenorphine, methadone, and naltrexone, fewer than 25% of individuals with opioid use disorder (OUD) receive evidence-based medication-assisted treatment (MAT). This significant treatment gap highlights a critical need for targeted education and support for healthcare professionals.

MAT is recognised as the gold standard in the treatment of OUD, shown to reduce illicit opioid use, prevent overdose, and promote sustained recovery. However, several barriers continue to limit its widespread adoption in clinical practice. These include persistent misconceptions about the nature of addiction and MAT, a lack of comprehensive provider training, and widespread stigma surrounding substance use disorders. Additionally, regulatory and administrative challenges have historically deterred providers from initiating MAT, although recent policy shifts, such as the elimination of the federal X-waiver requirement, aim to reduce these burdens.

Current gaps in practice include limited awareness among clinicians regarding these updated regulations, as well as insufficient understanding of the pharmacologic profiles, titration protocols, and contraindications associated with MAT medications. Moreover, many care models continue to implement MAT

in isolation, without the necessary integration of counselling, behavioural therapies, or recovery support services. Hesitancy among providers driven by fears of misuse, legal liability, or clinical complexity further contributes to the underutilization of MAT. Addressing these systemic gaps is essential for improving patient access to effective care and ultimately reducing the morbidity and mortality associated with opioid use disorder.

OBJECTIVES

Upon completion of this module, learners will be able to:

- **Differentiate** among the FDA-approved MAT options (buprenorphine, methadone, and naltrexone) regarding mechanism, clinical use, and safety profile.
- **Implement** evidence-based protocols for initiation, titration, and monitoring of MAT, including management of adverse effects and avoidance of precipitated withdrawal.
- **Navigate** updated regulatory frameworks governing MAT, including DEA training requirements and prescriptive authority.
- **Integrate** pharmacologic MAT with behavioural interventions and recovery support services to optimise long-term treatment outcomes.
- **Apply** clinical decision-making principles to select the most appropriate MAT for individual patient profiles, including those with comorbidities, pregnancy, or incarceration history.

GOALS

This program aims to help healthcare providers become more confident and skilled in using Medication-Assisted Treatment (MAT) by filling gaps in their knowledge about the medicines and rules involved. It also works to make MAT more available in different healthcare settings, so more people can get the help they need. By using MAT more effectively, we can lower the chances of relapse and overdose. Lastly, the program supports fair access to treatment by helping providers understand and reduce the barriers that underserved communities often face.

INTRODUCTION

The opioid crisis continues to escalate, with opioid use disorder (OUD) contributing to unprecedented levels of morbidity, mortality, and societal burden. Amid this public health emergency, **Medication-Assisted Treatment (MAT)** stands out as a cornerstone of effective, evidence-based care. By combining FDA-approved pharmacotherapies such as buprenorphine, methadone, and naltrexone with behavioural interventions and psychosocial support, MAT addresses the complex biological, psychological, and social dimensions of addiction.

Despite its proven efficacy in reducing opioid cravings, preventing overdose, and promoting sustained recovery, MAT remains significantly underutilised. Factors such as limited provider training, lingering stigma, regulatory hurdles, and fragmented care models continue to obstruct its full implementation. As recent policy changes aim to expand MAT access and streamline prescribing, there is an urgent need to equip healthcare professionals with the knowledge, confidence, and clinical tools necessary to deliver safe, integrated, and patient-centred treatment.

This article provides a comprehensive overview of MAT, highlighting current treatment gaps, medication profiles, regulatory updates, and best practices for safe prescribing. By strengthening provider capacity and promoting equitable access, MAT can become a transformative force in reversing the trajectory of the opioid epidemic and restoring lives.

FDA-APPROVED MEDICATIONS FOR OPIOID USE DISORDER (OUD): A PROFESSIONAL OVERVIEW

The Food and Drug Administration (FDA) has approved three primary medications for the treatment of Opioid Use Disorder (OUD): buprenorphine, methadone, and naltrexone. These medications, often used in conjunction with counselling and behavioural therapies (a comprehensive approach known as Medication-Assisted Treatment, or MAT), are highly effective in reducing opioid cravings, preventing withdrawal symptoms, and significantly lowering the risk of overdose and relapse. While all serve the critical purpose of treating OUD, they differ significantly in their mechanisms of action, indications, contraindications, and regulatory considerations.

BUPRENORPHINE

Buprenorphine is a partial opioid agonist that plays a pivotal role in the treatment of Opioid Use Disorder (OUD). Approved by the U.S. Food and Drug Administration (FDA), it is a cornerstone medication in Medication-Assisted Treatment (MAT), offering a safer and more accessible alternative to full opioid agonists like methadone.

First developed in the late 1960s and introduced into clinical practice in the 1980s, buprenorphine was initially used as an analgesic. Over time, its unique pharmacological profile, characterised by a ceiling effect on respiratory depression and a lower potential for misuse, made it an ideal candidate for addressing opioid addiction.

Today, buprenorphine is widely regarded as a safe, evidence-based, and life-saving intervention in combating the opioid epidemic. Its use, however, requires careful patient

assessment, monitoring, and adherence to regulatory frameworks to ensure optimal outcomes.

MECHANISM OF ACTION: BUPRENORPHINE

Buprenorphine exerts its therapeutic effects through a unique and well-characterised pharmacological profile, making it highly effective and comparatively safer for the treatment of **Opioid Use Disorder (OUD)**.

1. Partial Mu-Opioid Receptor Agonist

Buprenorphine binds to **mu-opioid receptors** in the central nervous system, the same receptors targeted by full opioid agonists such as **heroin, fentanyl, and oxycodone**. However, unlike full agonists that produce maximal receptor activation, buprenorphine acts as a **partial agonist**, meaning:

- It **activates** the receptor but only to a limited extent.
- It is **sufficient to alleviate cravings and withdrawal symptoms**.
- It **produces less euphoria and significantly reduces respiratory depression**, thereby lowering the risk of misuse and overdose.

2. High Affinity for Mu Receptors

Buprenorphine exhibits **exceptionally high receptor affinity**, meaning:

- It **binds tightly and persistently** to mu-opioid receptors.
- It can **displace full agonists** (e.g., heroin or morphine) from these receptors.
- This high binding affinity is therapeutically beneficial but necessitates **careful timing of initiation** in patients recently using full opioids, as it may trigger **precipitated withdrawal** if initiated prematurely.



Mechanisms of Buprenorphine Efficacy for Treatment of Opioid Use Disorder. Buprenorphine administration dose-dependently increases buprenorphine plasma concentration and occupancy of brain mu-opioid receptors (MORs) that translate into beneficial clinical outcomes. Through MOR occupancy, buprenorphine produces two types of effects: 1) opioid agonist effects in physically-dependent individuals (e.g., those with opioid use disorder) that include attenuation of opioid craving and withdrawal symptoms, and 2) blockade of the agonist effects of exogenous opioids (e.g., heroin, fentanyl) including drug liking and reinforcing effects (seeking/self-administration). Altogether, these agonist and blockade effects of buprenorphine, mediated by brain MORs at optimal concentration levels discussed herein, facilitate physiological stability, reduction in illicit opioid reinforcement and, in combination with other features of treatment, a shift toward natural sources of reinforcement to promote recovery.

3. Ceiling Effect on Opioid Activity

A distinctive feature of buprenorphine is its **"ceiling effect"**:

- After a certain dose, **increases in buprenorphine do not proportionally increase its opioid effects**.
- This applies especially to **respiratory depression**, which **plateaus** at higher doses an essential factor contributing to its **favourable safety profile** in overdose situations.
- This makes buprenorphine an ideal agent for **long-term maintenance therapy**.

4. Combination with Naloxone to Prevent Misuse

Buprenorphine is commonly co-formulated with **naloxone**, an opioid antagonist, in products like **Suboxone® and Zubsolv®**:

- When used **sublingually** (as prescribed), **naloxone has minimal systemic absorption** due to poor sublingual bioavailability and remains **clinically inactive**.
- If the combination product is **injected or misused intravenously**, naloxone becomes bioavailable and rapidly blocks opioid receptors, triggering **precipitated withdrawal**.
- This **deterrent mechanism discourages misuse**, enhancing the safety and integrity of treatment.

REGULATORY CONSIDERATIONS

Previously, doctors needed a special waiver (called the X-waiver) and specific training to prescribe buprenorphine for opioid use disorder (OUD). However, as of January 2023, this requirement has been removed. Now, any licensed healthcare provider with a valid DEA registration can prescribe buprenorphine for OUD. Still, a one-time 8-hour training on substance use disorders is required for DEA registration or renewal. Buprenorphine comes in different forms, like tablets, films, implants, and long-acting injections. Even though prescribing rules are now easier, combining medication with counselling and support is still the best practice.

BUPRENORPHINE: INDICATIONS AND CONTRAINDICATIONS

CATEGORY	DETAILS
INDICATIONS	
Treatment of OUD	FDA-approved for adults with moderate to severe Opioid Use Disorder.
Outpatient or Inpatient Use	Can be initiated in Office-Based Opioid Treatment (OBOT) or inpatient settings.
Mild to Moderate OUD	Preferred in patients with mild to moderate OUD, especially those seeking outpatient flexibility.
Maintenance Therapy	Suitable for long-term maintenance due to safety profile and once-daily dosing.

CATEGORY	DETAILS
CONTRAINDICATIONS	
Hypersensitivity	Known allergy to buprenorphine or naloxone (if using combination products like Suboxone®).
Severe Respiratory Depression	Avoid in patients with acute or uncompensated respiratory compromise.
Acute Opioid Intoxication	Do not initiate during early withdrawal or while full agonists are still active—risk of precipitated withdrawal.
Severe Liver Impairment	Use cautiously in advanced liver disease; monitor LFTs regularly.
Concurrent CNS Depressants	Risk of sedation and respiratory depression with benzodiazepines, alcohol, or other depressants; co-prescribing requires caution and patient education.

METHADONE

Methadone is a long-acting full opioid agonist that has been used for decades in the treatment of Opioid Use Disorder (OUD) and chronic pain. Originally developed in the 1940s as an analgesic, methadone became a cornerstone of addiction treatment in the 1960s due to its ability to suppress withdrawal symptoms, reduce opioid cravings, and block the euphoric effects of shorter-acting opioids like heroin and morphine.

However, methadone must be prescribed and dispensed under **strict federal regulations** through certified OTPs due to its potential for misuse, overdose, and respiratory depression. With careful dosing and monitoring, methadone remains a **highly effective, evidence-based treatment** for OUD, especially in individuals who have not responded to other therapies.

MECHANISM OF ACTION: METHADONE

Methadone is a **synthetic, long-acting opioid** with a complex mechanism that makes it highly effective in the treatment of **Opioid Use Disorder (OUD)** and chronic pain. Its pharmacologic properties support both **withdrawal management** and **maintenance therapy**.

1. Full Mu-Opioid Receptor Agonist

Methadone functions as a **full agonist** at the **mu-opioid receptors**, meaning:

- It **fully activates** the receptor, unlike partial agonists (e.g., buprenorphine).
- This results in **strong suppression of withdrawal symptoms**, **reduction in opioid cravings**, and **attenuation of euphoric effects** from other opioids due to receptor occupation.
- It helps stabilise the brain's reward system in individuals with severe opioid dependence.

2. Long and Variable Half-Life

Methadone has a **long and variable elimination half-life**, typically ranging from **24 to 36 hours**, with some variability up to 55 hours:

- Enables **once-daily dosing** in most OUD treatment settings.
- Provides **steady plasma levels**, minimising fluctuations that could otherwise lead to withdrawal or breakthrough cravings.
- This **sustained action** supports adherence and reduces the compulsive cycle of short-acting opioid use.

3. NMDA Receptor Antagonist Activity

In addition to its opioid effects, methadone **blocks N-methyl-D-aspartate (NMDA) receptors**:

- This property may help **modulate central sensitisation**, which is involved in **neuropathic pain** and **opioid tolerance**.
- NMDA antagonism may contribute to methadone's **ability to reduce craving intensity** and its effectiveness in **patients with complex pain and OUD comorbidity**.





REGULATORY CONSIDERATIONS

Methadone for Opioid Use Disorder (OUD) can only be prescribed and dispensed through federally regulated, SAMHSA-certified Opioid Treatment Programs (OTPs), commonly known as methadone clinics. Unlike buprenorphine, it is not available through office-based prescribing. Patients are typically required to attend daily for supervised dosing, especially early in treatment, with take-home doses allowed only after demonstrating treatment stability through factors like negative drug tests and adherence. While this strict regulation helps reduce misuse and ensures safety, it also limits access, particularly in rural or underserved areas due to the limited number of certified clinics.

CATEGORY	DETAILS
INDICATIONS	
Treatment of OUD	Used for detoxification and long-term maintenance in individuals with Opioid Use Disorder.
Chronic Pain	Indicated for the management of severe chronic pain not responsive to non-opioid treatments.
Alternative in OUD	Preferred for patients with: - Moderate to severe OUD - non-responders to buprenorphine - Need for structured care via certified Opioid Treatment Programs (OTPs)

CATEGORY	DETAILS
CONTRAINDICATIONS	
Hypersensitivity	Known allergy or hypersensitivity to methadone.
Respiratory Conditions	Severe respiratory depression, acute bronchial asthma, or advanced obstructive pulmonary disease.
MAO Inhibitor Use	Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation.
Paralytic Ileus	Contraindicated in patients with paralytic ileus (risk of worsening gastrointestinal stasis).
QTc Prolongation	Known QTc prolongation, other cardiac arrhythmias. ECG monitoring is essential during treatment.
Severe Liver Disease	Use with caution in advanced hepatic impairment due to the risk of drug accumulation.
CNS Depressants	Concurrent use with benzodiazepines, alcohol, or other CNS depressants increases risk of sedation, respiratory depression, and overdose.

NALTREXONE

Naltrexone is a **long-acting opioid receptor antagonist** approved by the FDA for the treatment of **Opioid Use Disorder (OUD)** and **Alcohol Use Disorder (AUD)**. Unlike agonists such as methadone or partial agonists

like buprenorphine, naltrexone **completely blocks opioid receptors**, particularly the **mu-opioid receptor**, preventing opioids from producing euphoria or reinforcing effects.

Because it has **no abuse potential, no physical dependence, and no withdrawal upon discontinuation**, naltrexone is especially suitable for **motivated individuals**, those who have completed detox, and **patients in structured environments** (e.g., post-incarceration, inpatient rehab). However, adherence and initiation challenges limit its widespread use compared to agonist-based therapies.

MECHANISM OF ACTION: NALTREXONE

Naltrexone is a **pure opioid antagonist** that exerts its therapeutic effects primarily by **blocking the mu-opioid receptor**, with additional activity at kappa and delta receptors. It does not activate these receptors, making it **non-reinforcing and non-addictive**.

1. Mu-Opioid Receptor Antagonism

Naltrexone **competitively binds** to mu-opioid receptors with high affinity, **preventing opioids** like heroin, morphine, or oxycodone from attaching and exerting their effects.

- Unlike agonists, it does **not produce euphoria or analgesia**.
- Its **strong receptor binding** can displace opioids already present, which is why **complete detoxification** is required before starting therapy.

2. Blocks Opioid-Induced Effects

By occupying opioid receptors, naltrexone **blocks the euphoric and sedative effects** of exogenous opioids.

- This **"blocking effect"** diminishes the reinforcing rewards of opioid use, helping prevent relapse.
- If a patient attempts to use opioids while on naltrexone, they typically experience **no subjective benefit**, which reinforces abstinence.



3. Reduction in Cravings

While naltrexone does not relieve withdrawal symptoms, it may **reduce cravings** by:

- **Blunting the brain's reward system** response to opioid cues.
- Modulating **endogenous opioid pathways** involved in stress and craving.

NALTREXONE: INDICATIONS AND CONTRAINDICATIONS

CATEGORY	DETAILS
INDICATIONS	
Opioid Use Disorder (OUD)	Approved for the prevention of relapse in adults with OUD after detoxification.
Alcohol Use Disorder (AUD)	Used to reduce alcohol cravings and prevent relapse in individuals with alcohol dependence.
Post-Detox Initiation	Suitable for patients who are opioid-free for 7-14 days to avoid precipitated withdrawal.
Formulations	Available in oral daily tablets and extended-release monthly injection (Vivitrol®); the injectable form is preferred for improved adherence in OUD treatment.

CATEGORY	DETAILS
CONTRAINDICATIONS	
Current Opioid Use	Actively using opioids or recent opioid use without adequate detoxification.
Positive Opioid Screen	A positive urine drug screen for opioids indicates recent use and risk for precipitated withdrawal.
Hypersensitivity	Known allergy or hypersensitivity to naltrexone or its components.
Liver Conditions	Acute hepatitis or severe liver failure; use with caution in liver impairment due to hepatic metabolism.
Pain Management Needs	Patients requiring opioid analgesia for acute or chronic pain should not use naltrexone, as it blocks opioid effects.

COMPARISON OF FDA-APPROVED MEDICATIONS FOR OUD

Feature	Buprenorphine	Methadone	Naltrexone
Mechanism	Partial Mu-opioid Agonist	Full Mu-opioid Agonist	Mu-opioid Antagonist
Effect on Opioid Receptors	Partially activates, high affinity, ceiling effect	Fully activated, high affinity, no ceiling effect	Blocks/inactivates, high affinity
Risk of Misuse/Diversion	Low to moderate (lower with naloxone)	High (full agonist with euphoria potential)	None (non-opioid) May cause precipitated
Withdrawal Management	Suppresses withdrawal (requires mild withdrawal before induction)	Suppresses withdrawal (can start immediately)	withdrawal if opioids are still present
Cravings	Reduces	Reduces	Reduces
"High" Feeling	Minimal to none (at therapeutic doses)	Minimal to none (stable dosing, blocks euphoria)	Prevented entirely by blocking opioid effects
Overdose Risk	Lower (ceiling effect limits respiratory depression)	Higher (full agonist, QTc prolongation)	None from naltrexone itself; risk if opioids are used to override the blockade or after stopping
Formulations	SL film/tablet, buccal film, implant, injectable (monthly)	Oral solution/tablet/disket	Oral tablet, extended-release IM injection (Vivitrol)
Dosing Frequency	Daily (or monthly for injectable)	Daily	Daily (PO) or monthly (IM)
Regulatory Setting	Office-based (no X-waiver needed post-2023)	Only through SAMHSA-certified OTPs	Any licensed prescriber (no special waiver/clinic)
Initiation Requirement	Patient must be in mild-moderate withdrawal (e.g., COWS ⩾12)	Can be started while actively using opioids	The patient must be opioid-free for 7-14 days

The choice of medication for OUD treatment is highly individualised and depends on factors such as patient preference, history of opioid use, co-occurring medical or psychiatric conditions, access to care, and the patient's readiness for treatment. All three FDA-approved medications are vital tools in addressing the opioid crisis and improving the lives of individuals with OUD

COMPREHENSIVE OVERVIEW: TREATMENT OF OPIOID USE DISORDER (OUD)

The treatment of Opioid Use Disorder (OUD) demands a comprehensive, evidence-based approach that acknowledges its chronic, relapsing nature. Effective interventions

emphasise patient-centred care, integrate pharmacotherapy with psychosocial support, ensure continuity of treatment, and foster collaboration across healthcare and judicial systems. Individuals with OUD frequently present with co-occurring physical and psychiatric disorders and polysubstance abuse, necessitating targeted interventions and meticulous monitoring for these comorbidities. Treatment initiation or continuation should never be halted due to incarceration; rather, the period of imprisonment presents a unique opportunity for engagement in vital therapeutic interventions.

CRISIS INTERVENTION: REVERSING OPIOID OVERDOSE

Prompt and effective response to acute opioid overdose is paramount. **Naloxone**, a short-acting opioid antagonist, is the criterion standard for reversing life-threatening respiratory depression and coma in overdose situations. The World Health Organisation (WHO) strongly advocates for widespread access to naloxone and comprehensive instruction in its administration for individuals likely to witness an opioid overdose.

- **Administration Routes:**
  Naloxone is effective via intravenous, intramuscular, and subcutaneous routes. Evidence suggests no inferiority of subcutaneous or intramuscular administration compared to intravenous.
- **Public Access and Formulations:**
  Recognising the critical need for immediate intervention outside of traditional healthcare settings, the FDA approved a 0.4 mg naloxone autoinjector for home use by family members or caregivers in 2014. This device provides visual and voice instructions and emphasises the necessity of seeking emergency medical care post-administration. Further enhancing accessibility, intranasal naloxone, available in ready-to-use 2 mg, 4 mg, or 8 mg single-dose sprayers, received FDA approval in 2015 after fast-track designation and priority review. Most notably, in 2023, the FDA approved 4 mg nasal spray naloxone for **over-the-counter (OTC) use**, a significant step in expanding public access to this life-saving medication.

HARM REDUCTION STRATEGIES

Harm reduction measures are critical for minimising the morbidity and mortality associated with opioid abuse and mitigating public health nuisances. A cornerstone of these efforts is preventing and reducing the frequency and severity of overdoses.

- **Opioid Agonist Therapy (OAT):**
  Enrolment in OAT with agents such as methadone and buprenorphine substantially

reduces the risk of overdose. Furthermore, OAT lessens the risk of infections (e.g., HIV, hepatitis) and other sequelae commonly associated with illicit opioid use.

DETOXIFICATION

Detoxification, the process of safely managing acute physical withdrawal symptoms, typically employs three primary modalities: opioid agonists, non-opioid medications, and, less commonly, rapid/ultra-rapid opioid detoxification.

- **Opioid Agonist-Assisted Detoxification:** The most frequently utilised method involves a slow, supervised detoxification where an opioid agonist, usually **methadone**, is substituted for the abused opioid. Methadone's once-daily dosing convenience and long half-life (approximately 22 hours) make it suitable for this purpose. However, its prolonged half-life can also make withdrawal more challenging than from shorter-acting opioids like heroin, and early dropout rates (30%-90%) and relapse rates can be high. **Buprenorphine** is another effective pharmacologic alternative for detoxification.
- **Non-Opioid Medications:** Many opioid withdrawal symptoms (e.g., restlessness, rhinorrhoea, lacrimation, diaphoresis, myosis, piloerection, cardiovascular changes) are mediated by increased sympathetic activation, primarily driven by hyperactivation of noradrenergic pathways stemming from the locus coeruleus. Non-opioid agents that inhibit these pathways, such as **clonidine**, have been used to manage acute withdrawal. The first non-opioid treatment specifically approved for opioid withdrawal symptom management is **lofexidine**, which has demonstrated reduced withdrawal severity and improved treatment completion rates in studies.
    - **Adjunctive Therapies:** Certain withdrawal symptoms, including anxiety and myalgias, may be resistant to clonidine. In such cases, **benzodiazepines** and **nonsteroidal anti-inflammatory drugs (NSAIDs)** may be necessary. Alpha-2 agonists, opioid agonist-antagonists, and antidepressants have also been employed to mitigate withdrawal symptoms and facilitate detoxification.

AGONIST REPLACEMENT THERAPY (MAINTENANCE TREATMENT)

For patients with OUD, guidelines from organisations such as the Department of Veterans Affairs Work Group strongly recommend offering either **buprenorphine/naloxone** or **methadone**

(within an opioid treatment program), prioritising patient preferences.

- **Goals:**
  The primary objective of opioid replacement therapy is to reduce illicit drug use and its associated health risks, with secondary goals encompassing reduced unsafe sexual practices, improved vocational and psychosocial functioning, and enhanced quality of life. The theoretical basis lies in addressing the endogenous opioid deficiency caused by chronic opioid use, thereby shifting the patient's focus from compulsive opioid seeking to more adaptive areas of life.

Methadone Maintenance Treatment (MMT)

- **Efficacy:**
  Methadone is recognised as the most empirically validated and cost-effective agent for OAT. Studies consistently demonstrate high one-year treatment retention rates (up to 80%) and significant reductions in illicit opioid use.
- **Initiation and Dosing:**
  Treatment typically begins with a dose of 25–30 mg, gradually titrated in 5- to 10-mg increments daily to a desired range of 60–120 mg. Research indicates that higher doses of methadone (generally >50 mg daily) are more effective than lower doses in reducing illicit opioid use and are comparable to high doses of buprenorphine (>8 mg daily) in terms of treatment retention and reduction of illicit opioid use.
- **Risk Evaluation:**
  The American Pain Society recommends an individualised medical and behavioural risk evaluation before methadone initiation, considering its specific pharmacological properties and adverse effect profile.
- **Contraindications:**
  Methadone is contraindicated in patients with known hypersensitivity to methadone hydrochloride, respiratory depression, acute bronchial asthma or hypercapnia, and known or suspected paralytic ileus.

Buprenorphine Maintenance Treatment

- **Advantages:**
  Buprenorphine offers several benefits over methadone, including generally lower cost, milder withdrawal symptoms upon abrupt cessation, a lower risk of overdose due to its partial agonist "ceiling effect," and a longer duration of action that can permit alternate-day dosing.
- **Patient Profile:**
  While specific subpopulations optimally suited for buprenorphine versus methadone are not definitively established, patients with less chronic and less severe heroin

dependence may benefit more significantly from buprenorphine.

- **Challenges:**
  Transitioning to buprenorphine from long-acting opioids can be challenging. The ASAM (American Society of Addiction Medicine) warns of potential diversion and misuse, as well as physical dependence. A significant risk of respiratory depression exists if buprenorphine is used concurrently with central nervous system depressants, including alcohol, other opioids, and illicit drugs. Neonatal withdrawal has also been reported with buprenorphine use during pregnancy. It is generally not recommended for patients with severe hepatic impairment.
- **Dosing and Safety:**
  Higher doses of buprenorphine (12 mg or greater) are more effective than lower doses in reducing illicit opioid use, with some studies demonstrating comparable efficacy to methadone on key treatment outcome measures. Buprenorphine's superior safety profile, particularly regarding overdose risk, remains its primary advantage over methadone.

Slow-Release Oral Morphine (SROM)

- **Alternative:** Slow-release formulations of morphine, effective with once-daily dosing, represent a viable alternative in OUD treatment. These formulations significantly delay the time to peak concentration after oral administration, leading to a delayed onset of action and minimising reinforcing effects.
- **Efficacy:**
  Several trials suggest that SROM has comparable efficacy to methadone, though definitive evidence is still emerging. SROM may be a suitable alternative for patients who are intolerant to methadone.

In conclusion, effective OUD treatment requires a nuanced understanding of its chronic nature, a robust crisis intervention strategy with widespread naloxone access, and the strategic deployment of pharmacotherapies (methadone, buprenorphine, naltrexone, and potentially SROM) integrated within a supportive psychosocial framework. Careful consideration of patient-specific factors, comorbidities, and the distinct characteristics of each medication is paramount for optimising treatment outcomes.

PHARMACOLOGIC SUMMARY: COMMON OUD FORMULATIONS

Drug (Examples)	Dose Range	Typical Starting Dose	Potential Adverse effect	Route(s)	DEA Schedule
Buprenorphine/ Naloxone (Suboxone, etc.)	Buprenorphine: 0.7-24 mg/day Naloxone: 0.18-6 mg/day	4/1 mg/day	Headache, nausea, pain, diaphoresis	SL film, SL tablet, buccal film	C-III
Methadone (Dolophine, Methadose)	20-120 mg/day	20-30 mg/day	Constipation, pruritus, cardiac arrhythmias (QTc)	PO, IV	C-II
Naltrexone (Vivitrol)	PO: 25-50 mg/day IM: 380 mg/month	PO: 25 mg/day IM: 380 mg/month	Injection site pain, anxiety, and dizziness	PO (tablet), IM (injection)	Not Scheduled
Buprenorphine (Sublocade, Probuphine)	SQ: 100-300 mg/month SL: 2-24 mg/day	SQ: 300 mg/month SL: 2-4 mg/day mg/month	Implant site pain, injection site reactions	SL tablet, SQ injection, implant	C-III

PHARMACOTHERAPY FOR ALCOHOL USE DISORDER (AUD)

Medications for AUD are a crucial element of comprehensive treatment, used for both **acute withdrawal management** and **relapse prevention**. They are most effective when combined with **psychosocial interventions**, such as cognitive-behavioural therapy (CBT), motivational enhancement therapy, and 12-step facilitation.

FDA-APPROVED MEDICATIONS FOR AUD

1. Disulfiram (Antabuse)

- **Mechanism:**
  Inhibits *aldehyde dehydrogenase*, leading to acetaldehyde accumulation → severe aversive reaction to alcohol (Disulfiram-Ethanol Reaction, DER).
- **Indication:**
  Maintenance of abstinence in patients committed to sobriety and under supervision.
- **Dosing:**
  250 mg/day; may increase to 500 mg. Reduce dose in patients >60 years.
- **Contraindications:**
  Cardiovascular/cerebrovascular disease, diabetes, renal/hepatic failure, psychosis, pregnancy, suicidality.
- **Precautions:**
  Avoid alcohol in all forms (e.g., foods, OTC meds). Risk of drug-drug interactions in older adults with polypharmacy.
- **Clinical Use:**
  Less favoured due to safety concerns and limited trial evidence. Often considered a last-line agent.

2. Naltrexone (ReVia – oral, Vivitrol – IM)

- **Mechanism:**
  Opioid antagonist → blocks alcohol's rewarding effects and reduces craving.
- **Oral Formulation:**
  - **FDA-approved:** 1994
  - **Dose:** 50–100 mg/day
  - **Efficacy:** Reduces relapse risk, heavy drinking, and cravings.
- **Injectable (Vivitrol):**
  - **FDA-approved:** 2006 (AUD), 2010 (OUD)
  - **Dose:** 380 mg IM monthly
  - **Use:** Only in patients abstinent for several days prior
- **Side Effects:**
  Nausea, dizziness, diarrhoea, light-headedness; injection site pain (IM only).
- **Contraindications:**
  Acute hepatitis, liver failure, pregnancy, breastfeeding, and adolescents.
- **Key Point:**
  Does *not* cause aversive reaction if alcohol is consumed. Patients should carry a medical

alert ID.

3. Acamprosate (Campral)

- **Mechanism:**
  Modulates *glutamate and GABA* neurotransmission → stabilises hyperexcitable post-alcohol withdrawal state.
- **FDA-approved:**
  2004
- **Dose:**
  666 mg (two 333-mg tablets) TID
- **Efficacy:**
  Enhances abstinence rates, delays time to first drink, and improves treatment retention.
- **Side Effects:**
  Diarrhoea, insomnia, dizziness, anxiety, weakness.
- **Contraindications:**
  Severe renal impairment.
- **Cautions:**
  Monitor renal function in older adults (≥65 years); may worsen depression or suicidality.

OFF-LABEL PHARMACOTHERAPIES FOR AUD

1. Baclofen

- **Mechanism:**
  GABA-B receptor agonist → reduces alcohol craving.
- **Dose:**
  Typically, 10 mg TID.
- **Efficacy:**
  May improve abstinence rates, especially in patients with liver disease.
- **Limitations:**
  Mixed evidence; no significant superiority in reducing heavy drinking/craving in meta-analyses.

2. Anticonvulsants

- **Topiramate**
  - **Mechanism:** Modulates GABA and glutamate to suppress craving.
  - **Dose:** Titrated from 25 to 300 mg/day.
  - **Efficacy:** Reduces heavy drinking, craving, and alcohol-related biomarkers.
  - **Side Effects:** Paraesthesia, fatigue, confusion, weight loss, taste changes.
- **Carbamazepine**
  - **Mechanism:** Stabilises neuronal excitability; used in alcohol withdrawal and maintenance.
  - **Dose:** Titrated to maintain 6 mg/L serum levels.
  - **Side Effects:** Drowsiness, liver toxicity, allergic reactions.
- **Oxcarbazepine**
  - **Mechanism:** Carbamazepine derivative with fewer adverse effects.
  - **Use:** Prevents relapse by reducing withdrawal symptoms.

- **Efficacy:** High-dose treatment showed >58% alcohol-free rate, outperforming both naltrexone and low-dose groups.



MEDICATIONS USED IN THE TREATMENT OF SUBSTANCE USE DISORDERS

Drug (Examples)	Dose Range	Typical Starting Dose	Potential Adverse effect	Route(s)	DEA Schedule
ALCOHOL USE DISORDER					
Acamprosate (Campral)	666 mg TID	666 mg TID	Diarrhoea	PO	Not scheduled
Naltrexone (Vivitrol)	PO: 25-100 mg/day IM: 380 mg/month	PO: 50 mg/day IM: 380 mg/ month	Injection site reactions, anxiety, syncope	PO, IM	Not scheduled
Disulfiram	125-500 mg/day	250 mg/day	Bitter taste, impotence, drowsiness	PO	Not scheduled

PHARMACOLOGIC TREATMENT OF TOBACCO USE DISORDER (TUD)

Pharmacotherapy is a **first-line** intervention for smoking cessation and is most effective when combined with **behavioural support**. The key approved options include:

FIRST-LINE AGENTS

1. Nicotine Replacement Therapy (NRT)

- **Forms Available:** Patches, gum, lozenges, inhalers, nasal sprays.
- **Mechanism:** Provides controlled nicotine doses to relieve withdrawal symptoms while eliminating harmful constituents of tobacco smoke.
- **Special Consideration: Not approved** for use in **pregnant or nursing women**; must be used cautiously in those with recent cardiovascular events.
- **Combination Therapy:** Long-acting (patch) + short-acting (gum/lozenge) NRT can improve cessation success.

2. Bupropion SR (Zyban)

- **Class:**
  Atypical antidepressant (dopamine and norepinephrine reuptake inhibitor).
- **Mechanism:**
  Reduces craving and withdrawal symptoms via dopaminergic and noradrenergic activity.
- **FDA-Approved For:**
  Smoking cessation since 1998.
- **Dosing:**
  Start 1 week before quit date; 150 mg daily x 3 days, then 150 mg twice daily. Duration: 7–12 weeks.
- **Evidence:**
  Cessation rates increase with dose (24.4% at 150 mg BID in trials). Combination with NRT improves quit rates.

- **Contraindications:**
  Seizure disorders, eating disorders, MAOI use, abrupt discontinuation of alcohol or sedatives.
- **Discontinuation Consideration:**
  If no progress after 7 weeks, discontinuing may be appropriate.

3. Varenicline Tartrate (Chantix)

- **Mechanism:**
  Partial agonist at α4β2 nicotinic acetylcholine receptors → reduces cravings and withdrawal, blocks nicotine's reinforcing effects.
- **FDA-Approved:**
  2006.
- **Dosing:**
  - Days 1–3: 0.5 mg once daily
  - Days 4–7: 0.5 mg twice daily
  - Day 8 onward: 1 mg twice daily
  - Initial course: 12 weeks; extend another 12 weeks if abstinent.
- **Efficacy:**
  More effective than bupropion (44% vs 30% quit rates); ~20% remain abstinent at 1 year.
- **Adverse Effects:**
  Nausea, insomnia, abnormal dreams, headache, potential neuropsychiatric effects (monitor patients).
- **Warnings:**
  - Increased nausea/fatigue when combined with NRT.
  - Production recall of **Chantix** in 2021 due to nitrosamine levels—**resolved as of May 2022**. Generic forms are available.
- **Behavioural Support:**
  The Manufacturer recommends combining with counselling.

SECOND-LINE (OFF-LABEL) OPTIONS

1. Clonidine

- **Class:** Alpha-2 adrenergic agonist; originally an antihypertensive.
- **Use:** Oral or transdermal route for smoking cessation.
- **Efficacy:** ~11% increase in quit rates.
- **Side Effects:** Sedation, dry mouth, dizziness, orthostatic hypotension.
- **Status:** Not FDA-approved for smoking cessation; reserved for those who failed first-line options.

2. Nortriptyline

- **Class:** Tricyclic antidepressant (TCA).
- **Mechanism:** Not clearly defined for smoking cessation; likely modulates norepinephrine and serotonin pathways.
- **Efficacy:** ~12% improvement in cessation rates over placebo.

- **Adverse Effects:** Dry mouth, constipation, weight gain, drowsiness, sexual dysfunction.
- **Limitations:** Few controlled trials; not FDA-approved; high side effect burden.

MEDICATIONS USED IN THE TREATMENT OF TOBACCO USE DISORDERS

Drug (Examples)	Dose Range	Typical Starting Dose	Potential Adverse effect	Route(s)	DEA Schedule
TOBACCO USE DISORDER					
Bupropion, sustained-release (Zyban)	150 mg daily or BID	150 mg/day	Weight loss, constipation, agitation, xerostomia, nausea	PO	Not scheduled
Nicotine	Gum: Up to a maximum of 30 pieces/day	Gum: 1 to 2pieces/hour (2mg/piece)	Oral irritation, headache, dyspepsia, nasal discomfort, cough, rhinitis	PO, intranasal, transdermal	Not scheduled
	Inhaler: 6-16 cartridges/day	Inhaler: 6 cartridges/day			
	Lozenge: Titrate to 1 lozenge every 4 to 8 hours	Lozenge: One lozenge every 1 to 2 hours			
	Nasal spray: Maximum 80 sprays/day	Nasal spray: 1 spray in each nostril once or twice per hour			
	Patch: One patch/day for 8 weeks	Patch: One patch/day			
Varenicline (Chantix)	1 mg BID up to 12 weeks	0.5 mg/day	Nausea, abnormal dreams, headache	PO	Not scheduled

BID = two times per day, DEA = Drug Enforcement Administration, IM = intramuscular, IV = intravenous, PO = oral, SL = sublingual, SQ = subcutaneous, TID = three times per day.



SAFE AND APPROPRIATE PRESCRIBING OF MEDICATIONS FOR OPIOID USE DISORDER (MAT)

Opioid Use Disorder (OUD) is a chronic, relapsing brain disease, and Medication-Assisted Treatment (MAT) is the gold standard for its management, significantly improving patient outcomes, reducing illicit opioid use, and decreasing overdose fatalities. Prescribing MAT medications (buprenorphine, methadone, and naltrexone) safely and appropriately requires a thorough understanding of patient selection, initiation, titration, ongoing monitoring, and the management of adverse effects or misuse.

GENERAL PRINCIPLES FOR MAT PRESCRIBING

1. **Comprehensive Assessment:**
   Always conduct a thorough medical, psychiatric, and substance use history. This includes current and past opioid use patterns, polysubstance use, co-occurring mental health conditions (which are common), and medical comorbidities (e.g., liver disease, cardiac issues).
2. **Patient-Centred Approach:**
   Involve the patient in shared decision-making. Discuss all FDA-approved MAT options, their mechanisms, benefits, risks, and regulatory requirements. Patient preference, prior treatment history, and lifestyle factors should guide the choice of medication.
3. **Informed Consent:**
   Obtain informed consent, ensuring the patient understands the chronic nature of OUD, the role of MAT, potential side

effects, risks (including overdose risk if medication is misused or abruptly stopped), and the importance of adherence to the treatment plan.

4. **Integrated Care:**
   Emphasise that MAT is most effective when integrated with psychosocial support (e.g., counselling, behavioural therapies). While not mandatory for all patients, it significantly enhances long-term recovery.
5. **Risk Mitigation:**
   Implement strategies to prevent diversion and misuse, including pill counts, urine drug screens (UDS), and prescription drug monitoring program (PDMP) checks.
6. **Continuity of Care:**
   Develop a plan for long-term management, including relapse prevention strategies and follow-up care.

COMPONENTS OF MEDICATION-ASSISTED TREATMENT (MAT) PROGRAMS

Medication-Assisted Treatment (MAT) is a comprehensive, evidence-based approach to treating substance use disorders. It integrates pharmacological, psychological, and supportive strategies to promote recovery, reduce relapse, and improve overall functioning.

1. FDA-Approved Medications

Core Function: Address the physiological effects of substance use.

- MAT programs rely on FDA-approved medications tailored to the specific substance of abuse (e.g., opioids, alcohol).
- These medications help to:
  - Stabilise brain chemistry
  - Reduce cravings
  - Block euphoric effects
  - Minimise withdrawal symptoms
- Examples include methadone, buprenorphine, and naltrexone for opioid use disorder; naltrexone, acamprosate, and disulfiram for alcohol use disorder.

2. Behavioural Therapies

Core Function: Treat the psychological and behavioural dimensions of addiction.

- Individual and group counselling helps patients understand the root causes of

addiction, develop coping strategies, and foster behavioural change.

- Common approaches:
  - Cognitive Behavioural Therapy (CBT)
  - Motivational Interviewing (MI)
  - Contingency Management
  - Relapse prevention and skills training
- These therapies empower patients to rebuild their lives and reduce the risk of recurrence.

3. Medical Monitoring and Clinical Oversight

Core Function: Ensure safe, effective, and personalised care.

- Ongoing medical assessments monitor the patients:
  - Physical and mental health
  - Medication response
  - Side effects and potential drug interactions
- Adjustments to treatment plans are made based on clinical findings.
- Includes urine drug screening, vital sign monitoring, and progress evaluations.

4. Recovery Support Services

Core Function: Reinforce treatment gains and promote long-term recovery.

- MAT programs incorporate wraparound services to address social, vocational, and emotional needs.
- Support may include:
  - Peer recovery groups (e.g., NA, AA, SMART Recovery)
  - Family and community support systems
  - Educational and employment assistance
  - Housing and transportation support
- These services foster stability, purpose, and a supportive environment for sobriety.

PRESCRIBING SPECIFIC MAT MEDICATIONS

1. Buprenorphine (often combined with Naloxone, e.g., Suboxone)

Patient Selection:

- **Ideal Candidates:**
  Patients with mild to moderate OUD severity; those seeking office-based treatment; individuals who can commit to regular follow-up; those with stable living situations.
- **Considerations:**
  Not suitable for patients in severe acute opioid withdrawal (risk of precipitated withdrawal). Patients must be in at least mild-to-moderate withdrawal before initiation.

Initiation (Induction):

- **Key Principle: Avoid Precipitated Withdrawal:**
  Buprenorphine has a high receptor affinity and can displace full opioids, leading to

acute, severe withdrawal if opioids are still significantly bound to receptors.

- **Opioid-Free Period:**
  Patients must be in a state of objective opioid withdrawal. This usually means no short-acting opioids for 12-24 hours and no long-acting opioids (e.g., methadone, extended-release oxycodone) for 24-72+ hours. Use a clinical opioid withdrawal scale (COWS) score of ≥12 as a guide for moderate withdrawal.
- **"Microdosing" Induction:**
  Newer strategies involve very small, escalating doses of buprenorphine while the patient is still on full agonists, followed by full induction, to minimise precipitated withdrawal, especially for patients on long-acting opioids. This requires close supervision.
- **Dosing:**
  Start with a low dose (e.g., 2-4 mg Sublingual Buprenorphine/Naloxone) in the office or home setting (if supervised). Observe for 1-2 hours for symptom relief and adverse effects. If withdrawal symptoms persist, administer additional doses (e.g., 2-4 mg) every 1-2 hours until symptoms are sufficiently managed.
- **First Day Target:**
  Aim for 8-12 mg total on day 1 for most patients.
- **Patient Education:**
  Thoroughly educate the patient on signs of precipitated withdrawal, proper sublingual administration, and what to expect.

Titration:

- **Goal:**
  Reach an effective maintenance dose that eliminates cravings and withdrawal symptoms without causing over-sedation or opioid effects.
- **Dosing Schedule:**
  Increase dose gradually over several days, typically by 2-4 mg increments, until the target dose is achieved.
- **Typical Maintenance Dose:**
  Ranges from 8 mg to 24 mg daily, with some patients requiring up to 32 mg. Doses higher than 24 mg are rarely needed due to the ceiling effect.
- **Frequency:**
  Once daily dosing is common, but some patients may benefit from split dosing (e.g., BID) to manage cravings throughout the day.

Monitoring for Effectiveness:

- **Clinical Assessment:**
  Regular follow-up visits to assess reduction in opioid cravings, absence of withdrawal symptoms, and decreased illicit opioid use.
- **Urine Drug Screens (UDS):**
  Routinely perform UDS to monitor for

adherence (presence of buprenorphine and metabolites) and continued polysubstance use (absence of illicit opioids and other substances like benzodiazepines or stimulants). Frequency should be individualised, but typically at least monthly, potentially more often initially.

- **PDMP Checks:**
  Regularly review the patient's PDMP history to identify any unprescribed controlled substance use, including "doctor shopping."
- **Psychosocial Functioning:**
  Assess improvements in social, occupational, and personal functioning.
- **Adherence:**
  Monitor medication adherence (e.g., pill counts, observed dosing if concerns arise).

Managing Adverse Effects or Misuse:

- **Common Side Effects:**
  Constipation, nausea, headache, sweating, dizziness, insomnia. Manage symptomatically.
- **Respiratory Depression:**
  Although less common than with full agonists due to the ceiling effect, risk increases when combined with other CNS depressants (e.g., benzodiazepines, alcohol). Educate patients on this risk and caution against concurrent use.
- **Precipitated Withdrawal:**
  Occurs during induction if initiated too early. Manage with supportive care and reassurance. In severe cases, discontinue buprenorphine and consider short-acting opioids to stabilise, then re-induce more cautiously.
- **Diversion/Misuse:**
  If suspected, increase monitoring (more frequent UDS, pill counts), reinforce education, consider observed dosing, and if necessary, escalate to a more structured treatment setting (e.g., methadone clinic) or consider injectable naltrexone. Document all concerns and interventions.
- **Hepatic Impairment:**
  Avoid in severe hepatic impairment; monitor liver function tests (LFTs) periodically, especially at initiation.

2. Methadone

Patient Selection:

- **Ideal Candidates:**
  Patients with moderate to severe OUD, long history of opioid dependence, those who have failed other MATs, pregnant patients (safest opioid agonist in pregnancy), and those requiring a highly structured treatment environment.
- **Considerations:**
  Requires daily attendance at a federally regulated Opioid Treatment Program

(OTP). Not suitable for patients unwilling or unable to attend daily.

Initiation (Induction) & Titration:

- **Setting:**
  Must be initiated and dispensed only within a SAMHSA-certified OTP.
- **Dosing:**
  Initial dose typically 20-40 mg, administered orally under direct observation.
- **Titration:**
  Doses are gradually increased (e.g., by 5-10 mg every few days) based on clinical response (absence of withdrawal/cravings, minimal sedation) until a stable maintenance dose is reached.
- **Typical Maintenance Dose:**
  Ranges from 60 mg to 120 mg daily, with some patients requiring higher doses. Higher doses are generally associated with better retention and reduced illicit use.
- **Peak Respiratory Depression:**
  Occurs 2-4 hours post-dose, while peak plasma levels are reached later. Close monitoring is crucial during titration to avoid respiratory depression.

Monitoring for Effectiveness:

- **Clinical Assessment:**
  Daily (initially) observed dosing, regular counselling sessions, assessment of cravings, withdrawal, and illicit drug use.
- **UDS:**
  Frequent, often random UDS per OTP regulations to monitor adherence and continued substance use.
- **PDMP Checks:**
  Regular review (if allowed by OTP protocol and state regulations).
- **ECG Monitoring:**
  Mandatory baseline ECG and repeat ECGs during dose titration and annually due to methadone's risk of QTc prolongation and Torsades de Pointes.
- **Take-Home Doses:**
  Earned progressively based on patient stability, adherence, negative UDS, and participation in counselling, per federal and state regulations.

Managing Adverse Effects or Misuse:

- **Common Side Effects:**
  Constipation (often severe, requires aggressive management), sweating, sedation, nausea, prolonged QTc.
- **Respiratory Depression/Overdose:**
  Higher risk than buprenorphine. Counsel patients on not sharing methadone, risks with CNS depressants, and warning signs of overdose. Naloxone availability for caregivers is crucial.
- **Diversion:**
  Highly regulated setting with observed dosing and strict take-home policies to

minimise diversion. If suspected, take-home privileges may be revoked.

- **QTc Prolongation:**
  Monitor ECGs. If QTc is significantly prolonged, dose reduction or switching to another MAT may be necessary.
- **Drug Interactions:**
  Methadone is metabolised by CYP enzymes (e.g., CYP2B6, CYP3A4). Many medications can interact, altering methadone levels (e.g., fluconazole, rifampin, phenytoin, HIV medications). Thorough medication reconciliation is essential.

3. Naltrexone (Oral and Extended-Release Injectable Vivitrol)

Patient Selection:

- **Ideal Candidates:**
  Patients highly motivated for abstinence, those recently detoxified from opioids, individuals with strong social support, patients with high-risk occupations (e.g., healthcare professionals), or those released from incarceration. Also effective for Alcohol Use Disorder.
- **Considerations:**
  Crucially, patients must be completely opioid-free for a minimum of 7-14 days (longer for methadone) before initiation. This is to prevent severe precipitated withdrawal.

Initiation:

- **Oral Naltrexone:**
  - **Opioid Clearance:** Verify opioid abstinence with a thorough history, UDS, and potentially a naloxone challenge test (administering a small dose of naloxone and observing for withdrawal symptoms; if none, indicates opioid absence).
  - **Dosing:** Start with a low-test dose (e.g., 0.5 mg oral naloxone or 25 mg oral naltrexone) and observe for withdrawal. If tolerated, proceed with the full dose.
  - **Daily Dosing:** 50 mg orally once daily.
- **Extended-Release Injectable Naltrexone (Vivitrol):**
  - **Opioid Clearance:** Same stringent requirement for opioid-free period.
  - **Dosing:** 380 mg intramuscular injection administered monthly by a healthcare professional into the gluteal muscle.
  - **Advantages:** Eliminates daily adherence issues common with oral formulations.

Titration:

- **Oral Naltrexone:**
  No titration needed, fixed daily dose.
- **Injectable Naltrexone:**
  No titration needed, fixed monthly dose.

Monitoring for Effectiveness:

- **Clinical Assessment:**

Regular follow-up to assess for cravings, continued abstinence from opioids, and overall psychosocial functioning.

- **UDS:**
  Routine UDS to monitor for other substance use (e.g., alcohol, stimulants), as naltrexone does not block non-opioid effects.
- **PDMP Checks:**
  Regular review.
- **Adherence:**
  For oral naltrexone, monitor adherence closely. Injectable naltrexone intrinsically ensures monthly adherence.
- **Education:**
  Reinforce that naltrexone blocks opioid effects, and attempting to overcome the block by using very large doses of opioids can be dangerous (risk of overdose once naltrexone wears off).

Managing Adverse Effects or Misuse:

- **Common Side Effects:**
  Nausea, vomiting, headache, dizziness, injection site reactions (for injectable form). Liver enzyme elevations can occur, so monitor LFTs periodically.
- **Precipitated Withdrawal:**
  The most critical risk if initiated too early. Requires supportive management.
- **Return to Use:**
  If a patient stops naltrexone and relapses, their opioid tolerance will be significantly reduced, dramatically increasing their risk of fatal overdose. Emphasise this risk and provide clear overdose prevention education (e.g., access to naloxone).
- **Pain Management:**
  Patients on naltrexone will not respond to opioid analgesics. Develop an alternative pain management plan (e.g., NSAIDs, regional blocks, non-opioid medications) if they require surgery or experience acute pain.

SPECIAL CONSIDERATIONS

- **Pregnancy:**
  Methadone is considered the safest and most effective MAT during pregnancy, as abrupt opioid withdrawal can be dangerous for the fetus. Buprenorphine is also an option. Naltrexone use in pregnancy is less studied and generally reserved for specific cases where patients are already stable on it.
- **Co-occurring Mental Health Disorders:**
  Address and treat co-occurring psychiatric conditions concurrently with OUD. Integrated care models lead to better outcomes.
- **Polysubstance Use:**
  Meticulously monitor and address concurrent use of other substances (e.g., alcohol, benzodiazepines, stimulants), as

this increases health risks and complicates OUD treatment.

- **Incarceration:**
  Advocate for the continuation or initiation of MAT during incarceration and seamless transition back to community-based treatment upon release. This is a crucial window for intervention and relapse prevention.

By adhering to these professional guidelines, clinicians can safely and effectively prescribe MAT medications, significantly impacting the lives of individuals struggling with OUD and contributing to a reduction in the public health burden



KEY CONCEPTS

MEDICATION	INITIATION PROTOCOL	TITRATION GUIDANCE
Methadone	Start at 10-30 mg/day based on opioid tolerance. Reassess after 3-4 hours 31.	Increase by 5-10 mg every 2-3 days. Target dose: 60-120 mg/day. Monitor for sedation/QT prolongation 31.
Buprenorphine	Begin in mild-moderate withdrawal (⩾8-12 hours post-short-acting opioid use). Initial dose: 2-4 mg, then increase by 2-4 mg/day 31.	Stabilise at ⩾8 mg/day. Consider long-acting injectables (Buvidal) for adherence 3.
Naltrexone	Confirm 7-10 days opioid-free. Start oral naltrexone (25 mg, then 50 mg/day) or injectable (380 mg/4 weeks) 12.	No titration needed. Monitor for precipitated withdrawal if relapse occurs 1.

CLINICAL CONSIDERATIONS

- Methadone: Use "start low, go slow" for opioid-naïve patients (e.g., 10 mg → 15 mg over 7 days) 3.
- Buprenorphine: Avoid precipitated withdrawal by delaying induction until withdrawal symptoms manifest



REGULATORY & SAFETY NOTES

- Methadone: Only dispensed through federally certified OTPs. Requires observed dosing initially 1.
- Buprenorphine: No X-waiver needed (post-2022). Prescribable by DEA-registered clinicians 12.
- Naltrexone: No special licensing; suitable for primary care but requires detox confirmation

Safe prescribing of MAT for OUD involves tailored patient selection, cautious initiation,

gradual titration, regular monitoring, and proactive management of adverse effects and misuse. Buprenorphine offers flexibility and safety, methadone suits severe cases in structured settings, and naltrexone supports relapse prevention in detoxified patients. Integrating MAT with psychosocial support and addressing access disparities are critical for the 2.7 million Americans with OUD (2020 data).

CONCLUSION

Medication-Assisted Treatment (MAT) represents a vital, evidence-based strategy in the management of opioid use disorder (OUD), offering a safe and effective path to stabilisation, recovery, and relapse prevention. By understanding the **mechanisms of action, pharmacologic profiles, and clinical applications** of buprenorphine, methadone, and naltrexone, healthcare providers can make informed decisions tailored to individual patient needs.

This module emphasised the importance of **safe initiation, titration, and monitoring of MAT**, alongside the need to assess for contraindications, manage potential adverse effects, and remain vigilant about treatment adherence and diversion risks. Beyond pharmacologic intervention, providers must also integrate MAT within a **holistic care model** that includes **psychosocial support, behavioural therapy, and peer-based recovery services**, ensuring comprehensive and sustainable care.

Finally, adherence to **federal and clinical guidelines,** including prescriptive authority, documentation, and compliance with regulatory frameworks, ensures the ethical and legal delivery of MAT across diverse healthcare settings. Equipped with this knowledge, clinicians are empowered to reduce barriers, destigmatise treatment, and support recovery trajectories that reflect compassion, clinical rigour, and long-term success.

REFERENCES

1. **Centers for Disease Control and Prevention (CDC)**. (2024). *Drug Overdose Deaths Remain High*. Retrieved from: https://www.cdc.gov
2. **Substance Abuse and Mental Health Services Administration (SAMHSA)**. (2023). *Medication-Assisted Treatment (MAT)*. Retrieved from: https://www.samhsa.gov/medication-assisted-treatment
3. **National Institute on Drug Abuse (NIDA)**. (2023). *Effective Treatments for Opioid Addiction*. Retrieved from: https://nida.nih.gov/publications
4. Wakeman SE, Barnett ML. (2023). *Primary Care and the Opioid-Overdose Crisis —*

Buprenorphine Myths and Realities. *New England Journal of Medicine*, 388:1203–1206.

5. Jones CM, Compton WM, et al. (2023). *Characteristics and Use Patterns Among Buprenorphine Recipients After Removal of the X-Waiver*. *JAMA*, 330(10):1029–1031.
6. U.S. Department of Health and Human Services. (2023). *Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder*. Retrieved from: https://www.hhs.gov